Is There a Link Between Cannabis and Lung Cancer?

Cannabis smoke can harm the lungs, and recent research has strengthened concern about a possible link with lung cancer. The evidence still does not establish a precise cancer risk for an individual who smokes cannabis, particularly someone who has never smoked tobacco. Older studies with no clear association should not be interpreted as proof that cannabis smoke is safe.

What Cannabis Smoke Does to the Lungs

According to the CDC’s lung-health guidance, cannabis smoke contains many of the same irritants, toxins, and cancer-causing chemicals as tobacco smoke. Smoking cannabis is associated with cough, mucus production, and bronchitis symptoms; those symptoms often improve after quitting. A joint, pipe, bong, or blunt does not eliminate exposure to smoke.

These respiratory effects and the presence of carcinogens are reasons for concern, but they are not the same as measuring how often cannabis smokers develop lung cancer. That requires human studies with reliable exposure histories and adequate follow-up.

What Older Lung-Cancer Studies Found

A 2015 pooled analysis combined six case-control studies, including 2,159 people with lung cancer and 2,985 controls. It found no clear overall association between habitual cannabis smoking and lung cancer after adjustment for factors including tobacco use: the pooled odds ratio was 0.96, with a 95% confidence interval of 0.66–1.38. Estimates for high exposure were imprecise, and the researchers could not exclude harm from heavy consumption.

A 2019 systematic review also found the lung-cancer evidence insufficient. Findings differed across studies, and common limitations included low cannabis exposure, limited information about cannabis-only smokers, and problems accounting for other risk factors. “Insufficient evidence” describes uncertainty; it does not establish a harmless exposure or a protective effect.

Newer Studies Add Concern, With Important Limits

A 2026 retrospective study in Lung Cancer examined electronic medical records from 67 U.S. healthcare organizations. After matching, each comparison group contained 149,632 adults. Those with a diagnosis of cannabis use disorder had a higher recorded risk of lung or bronchus cancer than those without that diagnosis: relative risk 3.87, with a 95% confidence interval of 3.43–4.38.

This is a substantial association, but it is not proof that cannabis caused those cancers. The exposure was a recorded cannabis use disorder diagnosis, not a standardized measure of how many joints someone smoked. The comparison group was people without that diagnosis, rather than necessarily people who had never used cannabis. Matching on recorded risk factors cannot eliminate unmeasured differences or incomplete exposure histories. The result should not be presented as a personal “fourfold risk” estimate for occasional users, edible users, or cannabis-only smokers.

A separate study published in CHEST in 2026 enrolled 150 people aged 60 or younger who already had lung cancer; 148 could be classified by smoking history. Of those, 39% smoked both cannabis and tobacco. Dual smokers had more emphysema and some more aggressive tumor types than tobacco-only smokers. Every cannabis smoker in this study also smoked tobacco. Because the participants already had cancer and there was no cannabis-only group, this study cannot determine the independent incidence of cancer caused by cannabis.

Why a Single Risk Number Remains Difficult

The studies above address different questions. Some compare recalled smoking exposure in people with and without cancer; others compare medical-record diagnoses or characteristics of patients who already have cancer. Their numbers cannot simply be averaged or treated as interchangeable.

Tobacco co-use is a particularly important complication. Other challenges include variation in smoking duration and intensity, incomplete medical records, relatively few heavily exposed cannabis-only participants, and the time cancer can take to develop. More recent observational findings warrant attention without erasing these limitations.

For tobacco, the causal link is firmly established. The CDC identifies cigarette smoking as the leading lung-cancer risk factor; radon, certain workplace exposures, and other factors also matter. There is no validated conversion that lets you substitute a number of cannabis joints for cigarette pack-years when estimating your cancer risk.

Practical Steps and When to Seek Care

Avoiding inhaled smoke removes that source of lung exposure. If you use cannabis medically, discuss the reason for treatment and possible alternatives with your clinician. Edibles avoid smoke inhalation but can cause delayed, unpredictable intoxication and poisoning. Vaping is not a proven cancer-prevention strategy: the CDC also documents serious vaping-associated lung injury, including the outbreak linked largely to THC products containing vitamin E acetate. A different delivery method does not make cannabis risk-free.

Tell your clinician about both cannabis and tobacco use, including the products, frequency, and duration. Seek assessment for a persistent or worsening cough, coughing up blood, unexplained weight loss, chest pain, or shortness of breath. These symptoms have several possible causes and should not automatically be attributed to routine smoker’s cough.

Screening is different from investigating symptoms. Under the U.S. Preventive Services Task Force recommendation, annual low-dose CT screening is recommended for adults aged 50–80 with at least 20 cigarette pack-years who currently smoke or quit within the past 15 years, subject to health and treatment suitability. Cannabis use alone is not an eligibility criterion in that recommendation. Discuss your individual risk and applicable screening guidance with your clinician; do not wait to meet screening criteria before seeking help for symptoms.